Series A · Biotech
Solstice Oncology raises $225m Series A for cancer immunotherapy
RA Capital Management led the financing to advance porustobart in two clinical indications.
Testing an immune therapy before surgery
Solstice is developing porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, for use with pembrolizumab before surgery. The company is evaluating the combination in a Phase 2 trial for stage II–III microsatellite-stable colon cancer and a second undisclosed indication.
Solstice focuses on the neoadjuvant setting, where treatment is given before an operation. The company says the Series A will advance porustobart across both indications; the candidate remains in clinical development.
Use of funds
Advance lead candidate porustobart in two clinical indications
Funding history
Series A · This round$225M